Atara Biotherapeutics (ATRA) Equity Ratio (2013 - 2026)

Atara Biotherapeutics has reported Equity Ratio for 14 years, with the latest figure at 1.87 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 110.19% year-over-year to 1.87; the trailing twelve-month figure through Mar 2026 stood at 1.87 (down 110.19% YoY), and the FY2025 full-year result was 1.9, down 113.38% from the prior year.
• Equity Ratio for Q1 2026 stood at 1.87, up from 1.9 in the prior quarter.
• The five-year high for Equity Ratio was 0.6 in Q4 2023, with the low at 1.9 in Q4 2025.
• Historically, Equity Ratio has averaged 0.43 across 5 years, with a median of 0.59 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio soared 78.21% — and 2024, when it tumbled 3225.27%.
• Atara Biotherapeutics' Equity Ratio stood at 0.34 in 2022, then soared by 78.21% to 0.6 in 2023, then slumped by 248.72% to 0.89 in 2024, then slumped by 113.38% to 1.9 in 2025, then grew by 1.94% to 1.87 in 2026.
• The last three Equity Ratio figures came in at 1.87 (Q1 2026), 1.9 (Q4 2025), and 1.21 (Q3 2025), per Business Quant data.